Neuraxis, INC (NRXS)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Net sales | 894,086 | 895,655 | 666,625 | 611,500 |
| Cost of goods sold | 146,643 | 139,475 | 97,050 | 73,458 |
| Gross profit | 747,443 | 756,180 | 569,575 | 538,042 |
| General and administrative | 2,264,729 | 2,856,768 | 2,052,996 | 2,628,288 |
| Research and development | 58,319 | 60,556 | 72,422 | 54,312 |
| Selling expenses | 142,253 | 133,954 | 95,430 | 62,274 |
| Operating loss | -1,717,858 | -2,295,098 | -1,651,273 | -2,206,832 |
| Other income | 40,993 | 16,820 | 17,072 | 2,961 |
| Other expense | - | - | 8,743 | 576,901 |
| Interest expense | 13,434 | 2,237 | 64,676 | 80,697 |
| Change in fair value of warrant liability | 119 | -1,831 | 6,726 | -7,576 |
| Amortization of debt discount and issuance cost | - | - | 40,888 | 63,817 |
| Financing charges | - | - | - | - |
| Total other income (expense), net | 27,440 | 16,414 | -103,961 | -710,878 |
| Net loss | -1,690,418 | -2,278,684 | -1,755,234 | -2,917,710 |
| Preferred stock dividends | 207,465 | 213,543 | - | - |
| Net loss available to common stockholders | -1,897,883 | -2,492,227 | -1,755,234 | -2,917,710 |
| Basic | 8,520,596 | 7,463,578 | 7,172,229 | 6,921,004 |
| Basic loss per share | -0.22 | -0.33 | -0.25 | -0.42 |
| Diluted | 8,520,596 | 7,463,578 | 7,172,229 | 6,921,004 |
| Diluted loss per share | -0.22 | -0.33 | -0.25 | -0.42 |